http://www.pharmexec.com/pharmexec/R%26D/Article/list/39724 Corporate strategies and tactics for more effective drug development. 2013-05-24T01:45:04Z http://www.pharmexec.com/pharmexec/Top+Feature/Pharmacies-mdash-A-New-Patient-Education-Opportuni/ArticleStandard/Article/detail/806473?contextCategoryId=39724&ref=25 Kenneth Getz of the Tufts Center for the Study of Drug Development looks at leveraging pharmacists as a channel to raise clinical research literacy among patient communities. 2013-02-25T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/092013/806473/pharmacy_drawer_176_flash.jpg HTML http://www.pharmexec.com/pharmexec/R%26D/Open-Innovation-in-Pharma-Defining-the-Dialogue/ArticleStandard/Article/detail/788391?contextCategoryId=39724&ref=25 There is much talk today about "open innovation" in business and research forums—but what exactly does it mean? How does open innovation as a concept apply to the pharmaceutical sector? Does it signal a change in the way pharmaceutical companies approach research and innovation? 2012-09-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/372012/788391null XML http://www.pharmexec.com/pharmexec/R%26D/Raising-the-Stakes-in-CNS/ArticleStandard/Article/detail/777872?contextCategoryId=39724&ref=25 As brands are required to produce more and more data to convince not only regulators, but payers, physicians, and patients, Jeffrey Jonas is pushing Shire's "search and develop" R&D model into new and sometimes uncomfortable territory. 2012-06-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/242012/777872/Photo-JJona-176_flash.gif XML http://www.pharmexec.com/pharmexec/R%26D/Managing-Information-Overload/ArticleStandard/Article/detail/773565?contextCategoryId=39724&ref=25 Companies know they need regulatory information management. What they don't always know is where to start and how to weave this vital capability across the enterprise. 2012-05-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/202012/773565null XML http://www.pharmexec.com/pharmexec/R%26D/The-Pharma-Revolution-Recalibrated/ArticleStandard/Article/detail/747598?contextCategoryId=39724&ref=25 Industry critics point to a lag in NME approvals as proof of innovation stagnation, but combination products and new delivery systems are quietly saving lives, and bringing in big dollars. 2011-11-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/452011/747598/light-bulb_thumbnail.jpg XML http://www.pharmexec.com/pharmexec/Global+Report/Front-and-Center-in-the-Fight-against-TB/ArticleStandard/Article/detail/739260?contextCategoryId=39724&ref=25 Pharm Exec talks to Dr. Mel Spigelman, President and CEO of the TB Alliance, about the organization's tuberculosis priorities. 2011-09-01T04:00:00Z XML http://www.pharmexec.com/pharmexec/Clinical+Trials/The-Power-of-Observation/ArticleStandard/Article/detail/739271?contextCategoryId=39724&ref=25 Observational studies present a compelling real-world corollary to the classic randomized clinical trial. 2011-09-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/372011/739271null XML http://www.pharmexec.com/pharmexec/Global+Report/Innovating-Around-Innovation/ArticleStandard/Article/detail/739259?contextCategoryId=39724&ref=25 Richard Barker, former Director General of ABPI, proposes a new agenda on how to restore public confidence in the value behind science. 2011-09-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/372011/739259/richard+barker_thumbnail.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/372011/739259null XML http://www.pharmexec.com/pharmexec/Company+Profiles/Complex-Biologics-The-View-from-Teva/ArticleStandard/Article/detail/739258?contextCategoryId=39724&ref=25 Industry and regulators alike must graple with the sensitivities associated with developing biosimilar drugs. 2011-09-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/372011/739258null XML http://www.pharmexec.com/pharmexec/Strategy/Cancer-From-Rut-to-Racetrack/ArticleStandard/Article/detail/730205?contextCategoryId=39724&ref=25 The objective is to make most cancers a curable, chronic condition. But with soaring costs, crowded therapeutic competition, and new diagnostic reimbursement challenges ahead, can industry deliver? 2011-07-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/282011/730205/driver_main.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/282011/730205/driver_flash.jpg XML http://www.pharmexec.com/pharmexec/Strategy/Planning-Beyond-the-Petri-Dish/ArticleStandard/Article/detail/730206?contextCategoryId=39724&ref=25 Pfizer's crizotinib development program combined organization, art, and science—and a large dose of unforeseen risk 2011-07-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/282011/730206null XML http://www.pharmexec.com/pharmexec/News+Analysis/Lilly-Kills-Two-Alzheimers-Trials/ArticleStandard/Article/detail/683730?contextCategoryId=39724&ref=25 In a huge blow to Eli Lilly's Alzheimer's pipeline, the drug giant was forced to end two clinical trials due to the fact that the treatment was actually making patients' memory recall worse. 2010-08-18T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/342010/683730null HTML http://www.pharmexec.com/pharmexec/News+Analysis/Amgen-Head-and-Neck-Cancer-Study-A-Disappointment/ArticleStandard/Article/detail/682763?contextCategoryId=39724&ref=25 Head-and-neck cancer treatment trial flops in Phase 3 trials causing Amgen stock to drop. The first-line therapy failed first and secondary goals compared with chemotherapy alone. 2010-08-11T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/332010/682763null HTML http://www.pharmexec.com/pharmexec/R%26D/Pfizer-Suspends-More-Tanezunab-Trials/ArticleStandard/Article/detail/679740?contextCategoryId=39724&ref=25 Just weeks after ending tanezunab clinical studies in osteoarthritis patients, the drug giant is ceasing additional trials for two other indications. 2010-07-20T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/302010/679740null HTML http://www.pharmexec.com/pharmexec/News+Analysis/Merck-Reveals-New-Trial-Network-for-Oncology/ArticleStandard/Article/detail/673535?contextCategoryId=39724&ref=25 Merck has established a stable of 15 to 20 investigators focused solely on cancer compounds in an effort to boost efficiency and help move along the bevy of oncology products the firm has in its pipeline. 2010-06-09T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/242010/673535null HTML http://www.pharmexec.com/pharmexec/News+Analysis/Clinical-Trial-Diversity-and-You/ArticleStandard/Article/detail/665250?contextCategoryId=39724&ref=25 Lilly's aggressive approach to shrinking the racial gap in drug trials might indicate big changes for the drugmaking process. 2010-04-14T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/162010/665250null HTML http://www.pharmexec.com/pharmexec/R%26D/Brave-Neuro-World/ArticleStandard/Article/detail/665667?contextCategoryId=39724&ref=25 Cognitive enhancement is a $20 billion market of aging Boomers, cramming students, global travelers, and battling soldiers. What's pharma going to do about it. 2010-04-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/162010/665667/Brave_thumbnail.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/162010/665667null XML http://www.pharmexec.com/pharmexec/R%26D/Managing-the-Three-Drivers-of-Risk-in-Drug-Develop/ArticleStandard/Article/detail/665660?contextCategoryId=39724&ref=25 Re-examining service provider roles can bring safety and speed on the road to registration. 2010-04-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/162010/665660/manging_thumbnail.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/162010/665660null XML http://www.pharmexec.com/pharmexec/R%26D/Two-Drugs-Fail-in-Trials/ArticleStandard/Article/detail/660853?contextCategoryId=39724&ref=25 Monday was a gloomy day for industry as two separate drug trials went belly up. AstraZeca's Recentin proved that it wasn't up-to-snuff compared with Avastin, and the Roche/Biogen Idec arthritis collaboration treatment, ocrelizumab, may have led to fatalities. 2010-03-10T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/112010/660853null HTML http://www.pharmexec.com/pharmexec/R%26D/Palpitations-in-the-Heart-of-US-Biotech/ArticleStandard/Article/detail/655245?contextCategoryId=39724&ref=25 California's biotech industry takes its own pulse in a new survey that tracks how the state is doing in serving as the nation's medicine cabinet and avatar of drug innovation. 2010-02-03T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/062010/655245null HTML http://www.pharmexec.com/pharmexec/News+Analysis/Witty-Opens-GSK-Library-for-Free-Access-to-Malaria/ArticleStandard/Article/detail/652833?contextCategoryId=39724&ref=25 GlaxoSmithKline announced that it would open up its library of prospective molecules and investigational vaccines. This move gives researchers free access to study experimental treatments for illnesses that plague the world's poorest countries. 2010-01-20T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/042010/652833null HTML http://www.pharmexec.com/pharmexec/News+Analysis/Gilead-and-Elan-Struggle-with-Clinical-Trials/ArticleStandard/Article/detail/648744?contextCategoryId=39724&ref=25 It's been a tough week for clinical trials: One drug got canned and another was re-tuned in the wake of failed end points and patient deaths. 2009-12-16T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/512009/648744null HTML http://www.pharmexec.com/pharmexec/R%26D/2010-Forecast-Key-Products-and-Leading-Therapeutic/ArticleStandard/Article/detail/647353?contextCategoryId=39724&ref=25 Alexandra Kibble of Thomson Reuters identifies the products and therapy areas to watch next year. 2009-12-08T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/502009/647353/Thomson-Reuters_thumbnail.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/502009/647353null HTML http://www.pharmexec.com/pharmexec/R%26D/Fight-or-Flight/ArticleStandard/Article/detail/648660?contextCategoryId=39724&ref=25 As the old orthodoxy shatters, pharma must stand firm or leave the field. 2009-12-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/512009/648660null XML http://www.pharmexec.com/pharmexec/R%26D/From-Promise-to-Payoff/ArticleStandard/Article/detail/648657?contextCategoryId=39724&ref=25 Our sixth annual pipeline report details 44 drugs that industry will be talking about in 2010. 2009-12-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/512009/648657null XML http://www.pharmexec.com/pharmexec/R%26D/Rising-to-the-Challenge-in-RampD/ArticleStandard/Article/detail/642667?contextCategoryId=39724&ref=25 Allosteric modulators are an emerging class of orally available small molecule drugs that may have multiple advantages compared to traditional drugs. 2009-11-18T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/472009/642667null HTML http://www.pharmexec.com/pharmexec/News+Analysis/Clinical-Trials-Find-Drug-Effective-In-Increasing-/ArticleStandard/Article/detail/642664?contextCategoryId=39724&ref=25 Dubbed as the 'female Viagra,' Boehringer Ingelheim's filbanserin represents an unprecedented step forward in treating female sexual dysfunction. 2009-11-18T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/472009/642664null HTML http://www.pharmexec.com/pharmexec/R%26D/Innovation-Over-Imitation/ArticleStandard/Article/detail/631735?contextCategoryId=39724&ref=25 As the first generation of biologics patents expire, companies are jokeying for position in follow-on biologics. 2009-11-04T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/412009/631735/Picture-9_thumbnail.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/412009/631735null XML http://www.pharmexec.com/pharmexec/R%26D/Biomarkers-Promises-and-Challenges/ArticleStandard/Article/detail/634081?contextCategoryId=39724&ref=25 Jerome Wilson and Martin Nemansky, explore some of the difficulties of implementing biomarkers during drug development. 2009-10-14T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/422009/634081null HTML http://www.pharmexec.com/pharmexec/R%26D/Finding-the-Sweet-Spot/ArticleStandard/Article/detail/631734?contextCategoryId=39724&ref=25 How proper site activation and site enrollment can help you get the most from clinical trials. 2009-10-02T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/412009/631734/Picture-10_thumbnail.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/412009/631734null XML http://www.pharmexec.com/pharmexec/News+Analysis/NHLBI-Cans-Sildenafil-Study-After-Reports-of-Sever/ArticleStandard/Article/detail/615239?contextCategoryId=39724&ref=25 Trial participants being treated for pulmonary hypertension suffered sickle cell pain in clinical trial. The cause: the active ingredient in Viagra. 2009-07-29T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/312009/615239null REMOTE http://www.pharmexec.com/pharmexec/News+Analysis/Statins-Get-Boost-from-New-Study/ArticleStandard/Article/detail/613031?contextCategoryId=39724&ref=25 Statins should be given to people with high blood pressure or diabetes, even if they don?t have heart disease, according to a study published in the British Medical Journal. 2009-07-22T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/302009/613031null REMOTE http://www.pharmexec.com/pharmexec/R%26D/The-Rx-for-RampD/ArticleStandard/Article/detail/613032?contextCategoryId=39724&ref=25 The process of research and development of new drugs has become phenomenally expensive. Can Lean Six Sigma revitalize the innovation process for pharmaceutical companies? 2009-07-22T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/302009/613032null HTML http://www.pharmexec.com/pharmexec/R%26D/Swallowing-the-Innovators-Rx/ArticleStandard/Article/detail/608965?contextCategoryId=39724&ref=25 Capitalize on the new age in healthcare with "disruptive innovation." 2009-07-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/282009/608965/PE0709_innovators_thumbnail.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/282009/608965null XML http://www.pharmexec.com/pharmexec/News+Analysis/ASCO-Roundup-Winners-Losers-and-Also-Rans/ArticleStandard/Article/detail/601559?contextCategoryId=39724&ref=25 Due to pharma's voluntary moratorium on doling out totefuls of freebies and all the lattes you can swallow, thousands of docs, researchers, and reporters had only their sleep-deprived selves to carry from data dump to data dump at this week?s American Society of Clinical Oncology (ASCO) annual confab in Orlando, Florida. 2009-06-03T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/232009/601559null REMOTE http://www.pharmexec.com/pharmexec/R%26D/How-Evidence-Based-Medicine-is-Impacting-Global-Cl/ArticleStandard/Article/detail/589174?contextCategoryId=39724&ref=25 Evidence-based medicine is fast becoming one of the key concepts in clinical and reimbursement practices in the developed world 2009-03-24T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/132009/589174null HTML http://www.pharmexec.com/pharmexec/News+Analysis/Pfizer-Pulls-Two-Late-stage-Drugs-from-Development/ArticleStandard/Article/detail/583389?contextCategoryId=39724&ref=25 A sign of the times or a rash decision? In an effort to curb unnecessary costs, Pfizer kills development of two late-stage products rather than sink more money into them. 2009-02-25T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/092009/583389null HTML http://www.pharmexec.com/pharmexec/Web+Exclusives/Transforming-Clinicians-into-Industry-Leaders/ArticleStandard/Article/detail/581513?contextCategoryId=39724&ref=25 Could physician behavior have a positive impact on Drug Development? 2009-02-13T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/072009/581513null HTML http://www.pharmexec.com/pharmexec/Special+Reports/Vaccines-for-All/ArticleStandard/Article/detail/580042?contextCategoryId=39724&ref=25 The world is suffering. But just over the horizon is a new access equation that could speed innovative vaccines to where they're needed most. 2009-02-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/062009/580042/PE0209_vaccine_flash.jpg XML http://www.pharmexec.com/pharmexec/News+Analysis/Pfizer-Sheds-More-Staff/ArticleStandard/Article/detail/575379?contextCategoryId=39724&ref=25 Sales reps aren't the only ones heading for the unemployment line - Pfizer is eliminating researcher positions as fewer drugs are making it to development. But could streamlining the crux of drug R&D cause more harm than good? 2009-01-14T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/032009/575379null HTML http://www.pharmexec.com/pharmexec/News+Analysis/Latest-Flu-Season-Sets-Tamiflu-Back-but-Doesnt-Kno/ArticleStandard/Article/detail/575384?contextCategoryId=39724&ref=25 The Tamiflu-resistant flu strain means increased sales for GSK's Relenza, but doesn't mean the end for the number-one antiviral. 2009-01-14T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/032009/575384null HTML http://www.pharmexec.com/pharmexec/R%26D/Insuring-Global-Clinical-Trials/ArticleStandard/Article/detail/574732?contextCategoryId=39724&ref=25 As global regulators set up rules for liability insurance for clinical trials, the playing field has grown complex for sponsors. This article reviews the key issues and offers a look at how European, Asian, and Latin American countries handle clinical trial insurance. 2009-01-09T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/022009/574732null HTML http://www.pharmexec.com/pharmexec/News+Analysis/Merck-Submits-Request-to-Market-Gardasil-to-Men/ArticleStandard/Article/detail/574235?contextCategoryId=39724&ref=25 Merck isn't bragging about the positive data it received regarding the use of its landmark HPV vaccine in men. But the pharma giant also isn't wasting time submitting the info to FDA. Pharm Exec talked to the lead investigator behind the trials to find out why this could be another milestone for Merck. 2009-01-07T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/022009/574235null HTML http://www.pharmexec.com/pharmexec/R%26D/Site-Activation-The-Key-to-More-Efficient-Clinical/ArticleStandard/Article/detail/571374?contextCategoryId=39724&ref=25 A new study of hundreds of thousands of clinical trial records reveals that the overall length of a trial is directly related to how long it takes to activate the study sites - and that most companies are wasting precious weeks and even months in activation. Here's how to improve your performance. 2008-12-12T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/502008/571374null HTML http://www.pharmexec.com/pharmexec/Special+Reports/The-2008-Pipeline-Report/ArticleStandard/Article/detail/570131?contextCategoryId=39724&ref=25 We scrub industry's pipeline to find the drugs that everyone will be talking about in 2009 and beyond 2008-12-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/492008/570131/PE1208_pipeline_flash.jpg XML http://www.pharmexec.com/pharmexec/R%26D/Gilding-Lilly/ArticleStandard/Article/detail/566074?contextCategoryId=39724&ref=25 Some say it's just another pharma facing its patent cliff. But others say this company's got it worse. With new CEO John Lechleiter in charge, can Lilly find its way back from the edge? 2008-11-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/462008/566074/PE1108_lilly_flash.jpg XML http://www.pharmexec.com/pharmexec/R%26D/Evolving-Clinical-Trials/ArticleStandard/Article/detail/557676?contextCategoryId=39724&ref=25 Clinical trials need to change. A recent survey shows that industry should address the research supply chain for the greatest gains in effciency. 2008-10-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/412008/557676null XML http://www.pharmexec.com/pharmexec/News+Analysis/GSK-Restructures-Oncology-Division/ArticleStandard/Article/detail/550565?contextCategoryId=39724&ref=25 Glaxo's cancer departments will be consolidated into one big division encompassing discovery, research, and trials. The move is expected to cost some jobs, but GSK hopes it will strengthen synergy within its R&D unit. 2008-09-17T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/382008/550565null HTML http://www.pharmexec.com/pharmexec/R%26D/Unleash-the-Dragon-2/ArticleStandard/Article/detail/548224?contextCategoryId=39724&ref=25 Concerns over quality? It's not stopping Big Pharma outsourcing and venture capital. 2008-09-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/372008/548224/PE0908_china_flash.jpg XML http://www.pharmexec.com/pharmexec/Article/Publish-or-Perish/ArticleStandard/Article/detail/548226?contextCategoryId=39724&ref=25 FDAAA means that you need to register clinical trials—and not only for publication planning 2008-09-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/372008/548226null XML http://www.pharmexec.com/pharmexec/R%26D/Roche-Touts-Positive-Data-for-Investigational-Diab/ArticleStandard/Article/detail/522918?contextCategoryId=39724&ref=25 Swiss pharma giant Roche was abuzz at ADA, announcing that its new diabetes treatment is set for Phase III trials and commenting on future plans for failed CETP inhibitor dalcetrapib. 2008-06-11T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/242008/522918null HTML http://www.pharmexec.com/pharmexec/News+Analysis/Risky-Cholesterol-Drug-Proves-Positive-for-Roche/ArticleStandard/Article/detail/507004?contextCategoryId=39724&ref=25 While some drugmakers are being pummeled for data on their "bad" cholesterol?lowering drugs, promising Phase II stats about its "good" cholesterol?raising CETP inhibitor has Roche smiling. Can it escape the torcetrapib curse? 2008-04-02T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/142008/507004null HTML http://www.pharmexec.com/pharmexec/Rotating+Feature+Article/In-Praise-of-Independence-QampA-with-Roches-Dan-Za/ArticleStandard/Article/detail/501204?contextCategoryId=39724&ref=25 Roche has always gone its own way with biologics, deals, and new medicines. Now that the rest of industry has caught on, how can Roche stay ahead of its time? 2008-03-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/102008/501204/pe0308_roche_flash.jpg XML http://www.pharmexec.com/pharmexec/Rotating+Feature+Article/Fight-Resistance/ArticleStandard/Article/detail/490703?contextCategoryId=39724&ref=25 US officials think they can control MRSA and other "superbugs," but dangerous bacteria know no boundaries. What does the world do when its drugs stop working? 2008-02-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/072008/490703/RESISTANCE_flash.jpg XML http://www.pharmexec.com/pharmexec/R%26D/BioMS-Medical-Signs-500-Million-Agreement-with-Lil/ArticleStandard/Article/detail/482390?contextCategoryId=39724&ref=25 Eli Lilly will help develop and market BioMS?s secondary progressive multiple sclerosis drug MBP8298, now in Phase III trials. If approved, the drug will be one of the only medications on the market to treat late-stage MS, a boon for both Lilly and BioMS. 2008-01-09T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/022008/482390null HTML http://www.pharmexec.com/pharmexec/Articles/Pharma-Forecast-Into-the-Woods/ArticleStandard/Article/detail/483070?contextCategoryId=39724&ref=25 Pharm Exec asks experts to predict what 2008 has up its sleeve for the industry--from the top line to the bottom line, from R&D to M&As, from Congress to the courts. 2008-01-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/022008/483070/salesforce_thumbnail.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/022008/483070/main_main.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/022008/483070/forecast_flash.jpg XML http://www.pharmexec.com/pharmexec/Articles/RampD-Learning-to-Share/ArticleStandard/Article/detail/483069?contextCategoryId=39724&ref=25 Novartis' Paul Herrling talks about how Big Pharma can learn from nonprofit R&D and collaborate to get an edge on the drug safety problem. 2008-01-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/022008/483069/PE0108r+d_flash.jpg XML http://www.pharmexec.com/pharmexec/Articles/The-Pharm-Exec-Pipeline-Report-2007/ArticleStandard/Article/detail/476125?contextCategoryId=39724&ref=25 You couldn't call it a gusher, but the pipeline has still has some life in it, and important new therapies are working their way toward approval. Have we turned the corner? Judge for yourself, with the help of this guide to 61 of the best new products in development. 2007-12-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/482007/476125/pipeline_flash.jpg XML http://www.pharmexec.com/pharmexec/R%26D/Special-Delivery/ArticleStandard/Article/detail/476132?contextCategoryId=39724&ref=25 Getting innovative drugs into bodies just got a whole lot more interesting. Here's how the delivery biz is keeping up with pharma's R&D. 2007-12-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/482007/476132/specialdelivery_flash_flash.jpg XML http://www.pharmexec.com/pharmexec/Articles/Rethinking-Vaccines-QampA-with-Jane-Quinn-GlaxoSmi/ArticleStandard/Article/detail/476128?contextCategoryId=39724&ref=25 There are plenty of new vaccines on the market, but for patients to get maximum benefit from them, payers and even physicians need to rethink their roles in prevention. 2007-12-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/482007/476128null XML http://www.pharmexec.com/pharmexec/News+Analysis/Duke-Partners-with-FDA-to-Modernize-Clinical-Trial/ArticleStandard/Article/detail/475929?contextCategoryId=39724&ref=25 In an attempt to bring clinical trials into the 21st century, FDA and Duke launched a public–private partnership that will look at the current state of trials and determine what tools can be implemented to make trials safer and more efficient. 2007-11-29T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/482007/475929null HTML http://www.pharmexec.com/pharmexec/News+Analysis/Lillys-New-Blood-Thinner-No-Blockbuster/ArticleStandard/Article/detail/470634?contextCategoryId=39724&ref=25 Safety Risks, Generic Threat Scale Down Big Hopes 2007-11-06T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/452007/470634null HTML http://www.pharmexec.com/pharmexec/Current+Issue/India-vs-China/ArticleStandard/Article/detail/469185?contextCategoryId=39724&ref=25 Will CROs continue to operate in India, or will Novartis' pullout send them farther East? 2007-11-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/442007/469185null XML http://www.pharmexec.com/pharmexec/Current+Issue/More-Confidencemdashor-Slower-Development/ArticleStandard/Article/detail/469184?contextCategoryId=39724&ref=25 FDAAA aims to restore public trust in drug safety regulation but may curb investment in R&D 2007-11-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/442007/469184null XML http://www.pharmexec.com/pharmexec/News+Analysis/Eli-Lilly-Quietly-Suspends-Two-Trials/ArticleStandard/Article/detail/469014?contextCategoryId=39724&ref=25 The company halts two small pharmacodynamic trials of a key candidate just days before a major presentation of data. Is something wrong with prasugrel? And why is Lilly playing the news so close to the chest? 2007-10-31T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/442007/469014null HTML http://www.pharmexec.com/pharmexec/News+Analysis/Genzyme-Forms-Partnership-with-Overseas-Gene-Thera/ArticleStandard/Article/detail/469010?contextCategoryId=39724&ref=25 Genzyme will collaborate with Chinese biotech manufacturer Sunway to perform clinical trials and potentially produce the experimental gene therapy HIF-1a in China. 2007-10-31T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/442007/469010null HTML http://www.pharmexec.com/pharmexec/News+Analysis/Medtronic-Wins-Recommendation-for-Safer-Drug-Eluti/ArticleStandard/Article/detail/465613?contextCategoryId=39724&ref=25 FDA advisory panel notes high efficacy—and no thrombosis after six months—in clinical trials. Nonetheless, Medtronic's stents will be under close postapproval watch. 2007-10-17T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/422007/465613null HTML http://www.pharmexec.com/pharmexec/News+Analysis/BMS-Snags-Biotech-Firm-Adnexus/ArticleStandard/Article/detail/461948?contextCategoryId=39724&ref=25 Adnexus' protein-building technology could spell new drugs and big profits for BMS--if the drug development engine works. 2007-10-03T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/402007/461948null HTML http://www.pharmexec.com/pharmexec/Articles/Its-Standards-Time/ArticleStandard/Article/detail/463120?contextCategoryId=39724&ref=25 The clinical trials space these days is an alphabet soup of technologies: CTMS (clinical trial management systems); CDM (clinical data management); CDR (clinical data repositories); eCTD (electronic common technical document); and many more. But the technology with the most promise for transforming the way clinical trials are performed (and for driving everyone mad throughout implementation) is EDC—electronic data capture. It's taken more than a decade, but today most big pharma companies—and a fair number of smaller ones—are using some form of EDC in clinical trials. The early adopters might have experienced some growing pains, but the benefits seem to be outweighing the high cost of implementation. Few companies would consider going back to paper-based trials. 2007-10-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/402007/463120null XML http://www.pharmexec.com/pharmexec/Current+Issue/Radio-Active/ArticleStandard/Article/detail/463112?contextCategoryId=39724&ref=25 David Barlow is the closest thing you can find to a pharma-industry ecologist. He takes companies that deal with technology that Big Pharma won't touch and turns them into drug powerhouses. 2007-10-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/402007/463112null XML http://www.pharmexec.com/pharmexec/Articles/RampD-Innovation-An-Answer-to-Cancer/ArticleStandard/Article/detail/463103?contextCategoryId=39724&ref=25 Cancer R&D IS booming right now. At a time of poor ratings on both Wall Street and Main Street, pharma can at least point proudly to its oncology pipeline as proof that it still takes big risks to make big advances against big killers—and win. According to a recent IMS report, the cancer pipeline contains 380 compounds, with nearly 100 in Phase III. The long-established standard of care—surgery, radiotherapy, and chemo—is fast giving way to a high-tech array of targeted therapies. These molecules and antibodies are designed to block specific disease pathways, and they are proving both far more effective and far more tolerable than the sledgehammer status quo. Since 1996, the overall survival rate for patients has jumped by 30 percent, from one-half to two-thirds. 2007-10-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/402007/463103null XML http://www.pharmexec.com/pharmexec/News+Analysis/GSK-Boosts-Flu-Doses/ArticleStandard/Article/detail/458135?contextCategoryId=39724&ref=25 Drug company increases vaccine supply by 10 million in advance of influenza season 2007-09-19T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/382007/458135null HTML http://www.pharmexec.com/pharmexec/News+Analysis/New-Rules-for-Asthma-Med-Makers/ArticleStandard/Article/detail/454640?contextCategoryId=39724&ref=25 NHLBI releases updated regulations for asthma treatment 2007-09-06T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/362007/454640null HTML http://www.pharmexec.com/pharmexec/Current+Issue/Incentives-Incense-Industry-in-UK/ArticleStandard/Article/detail/455798?contextCategoryId=39724&ref=25 The Association of the British Pharmaceutical Industry is challenging the UK government over the financial incentives being offered by the Department of Health (DH) to encourage doctors to switch patients from on-patent medicines to specific generic alternatives. ABPI believes the way the incentives are structured contravenes EU law—if pharma companies were to offer similar payments, they would be in serious trouble. 2007-09-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/372007/455798null XML http://www.pharmexec.com/pharmexec/Articles/RampD-A-Merck-in-Progress/ArticleStandard/Article/detail/455801?contextCategoryId=39724&ref=25 That was the collective vow sworn by Big Pharma last December following Pfizer's $1 billion–down–the–tubes withdrawal of the cholesterol compound they had touted as the most important drug of the decade. The question is, What's the right organizational construct to support innovation—or at least to stop Phase III failures? 2007-09-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/372007/455801null XML http://www.pharmexec.com/pharmexec/Global+Report/Make-Resistance-Futile/ArticleStandard/Article/detail/446935?contextCategoryId=39724&ref=25 Scare stories about antibiotic-resistant bacteria are all too common in the mass media these days. In the United Kingdom alone, the number of deaths from methicillin-resistant Staphylococcus aureus almost doubled between 2001 and 2005 to more than 2,000. The situation with Clostridium difficile is even worse, with UK deaths tripling to almost 4,000 over the same period. The big problem is that the incidence is growing, yet few antibiotics are being developed that will be able to kill the resistant bacteria. 2007-07-30T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/312007/446935null XML http://www.pharmexec.com/pharmexec/R%26D/Tomorrows-Drugs/ArticleStandard/Article/detail/446938?contextCategoryId=39724&ref=25 Have you heard the rumors that all the drugs have already been discovered? Well, forget it. Maybe some of the low-hanging fruit is gone—but in the last few years, science has opened up thousands of new targets, while new technologies have made it possible to treat disease in unprecedented ways. 2007-07-30T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/312007/446938null XML http://www.pharmexec.com/pharmexec/Thought+Leader/Connected-Markets-Rob-Dhoble/ArticleStandard/Article/detail/442274?contextCategoryId=39724&ref=25 We'll see a more coordinated, worldwide platform not just for marketing, but for R&D and regulatory because of the harmonization that is slowly coming, primarily between Japan, Europe, and the United States 2007-07-03T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/292007/442274null XML http://www.pharmexec.com/pharmexec/R%26D+News/Glaxo-Gives-High-Five-to-Cancer-Market/ArticleStandard/Article/detail/437611?contextCategoryId=39724&ref=25 Big crop of oncology drugs is the fruit of Garnier's excellent restructuring 2007-06-27T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/262007/437611null HTML http://www.pharmexec.com/pharmexec/R%26D+News/Global-Access-for-Pfizers-New-HIV-Drug/ArticleStandard/Article/detail/435689?contextCategoryId=39724&ref=25 Maraviroc's promise shows the value of expanded-access programs 2007-06-20T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/252007/435689null HTML http://www.pharmexec.com/pharmexec/R%26D+News/Whats-Hot-and-Whats-Not-in-Oncology/ArticleStandard/Article/detail/432937?contextCategoryId=39724&ref=25 The take-home from the American Society of Clinical Oncology. 2007-06-13T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/232007/432937null HTML http://www.pharmexec.com/pharmexec/R%26D+Articles/Clinical-Trials-Under-Scrutiny/ArticleStandard/Article/detail/429165?contextCategoryId=39724&ref=25 Payment to physicians and other conflicts of interest Are ripe areas of concern, particularly when they raise doubt over the integrity of research findings 2007-06-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/212007/429165null XML http://www.pharmexec.com/pharmexec/R%26D+News/Companies-Forge-Ahead-with-Cancer-Vaccine-RampD/ArticleStandard/Article/detail/428442?contextCategoryId=39724&ref=25 Provenge setback not deterring others in the field. 2007-05-23T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/212007/428442null HTML http://www.pharmexec.com/pharmexec/R%26D+News/Pharma-Gets-Wired-for-Clinical-Trials/ArticleStandard/Article/detail/426643?contextCategoryId=39724&ref=25 Companies are poised to speed up investments in electronic data capture. 2007-05-16T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/202007/426643null HTML http://www.pharmexec.com/pharmexec/Regulatory/Kid-Tested-Government-Approved/ArticleStandard/Article/detail/423216?contextCategoryId=39724&ref=25 As the industry focuses its attention on the upcoming renewal of the Prescription Drug User Fee Act (PDUFA), there is a tendency to overlook two other significant pharmaceutical programs coming up for renewal and a related piece of legislation that has been introduced: 2007-05-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/182007/423216/kid_thumbnail.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/182007/423216null XML http://www.pharmexec.com/pharmexec/R%26D+News/Generic-Biologics-Booked-for-Arrival/ArticleStandard/Article/detail/419953?contextCategoryId=39724&ref=25 With legislation pending in Congress, generics makers begin investments in follow-on protein drugs. 2007-04-18T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/162007/419953null HTML http://www.pharmexec.com/pharmexec/Articles/Virus-as-Viable-Drug/ArticleStandard/Article/detail/401668?contextCategoryId=39724&ref=25 A lot of the viruses that are being worked on today are genetically engineered to target the cell and crank out a drug that will kill it. But in our case, we don’t need a drug—the reovirus does it all by itself. 2007-02-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/052007/401668/TN_thumbnail.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/052007/401668null XML http://www.pharmexec.com/pharmexec/Toolkit/Toolkit-Going-Head-to-Head/ArticleStandard/Article/detail/401660?contextCategoryId=39724&ref=25 Comparative drug tests make pharma see red. But market pressure to prove a drug's real-world value is likely to force even the most stubborn firm into the ring. Why be bull-headed? Adaptive trials can cut cost, time, and risk in half. 2007-02-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/052007/401660null XML http://www.pharmexec.com/pharmexec/Thought+Leader/Thoughtleader-John-Bailye-Dendrite/ArticleStandard/Article/detail/401658?contextCategoryId=39724&ref=25 Doctors want to know what's hot in the market, not read a new brochure on a nine-year product that doctors have already been using. 2007-02-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/052007/401658null XML http://www.pharmexec.com/pharmexec/Articles/Pipeline/ArticleStandard/Article/detail/389274?contextCategoryId=39724&ref=25 This year's Pipeline Report profiles 32 compounds that are the early fruit of pharma's investment in targeted drug design. In diabetes, HIV, hepatitis C—and especially oncology—vibrant R&D is set to revolutionize treatment with new classes of drugs over the coming decade. We spotlight today's geeky names—the DPP-IVs and MK-0518s, the Tykerbs and Telaprevirs—that are most likely to be tomorrow's glam blockbusters. Even the year's downers—we're still waiting on Acomplia, Exubera is failing to live up to the hype—are reminders of how improvements in drug development, such as Phase 0, are helping industry in its drive to become more effective. Although riskier than squeezing me-too drugs out of proven products, targeted R&D is lighting pathways not only to cures of killer diseases but to a fresh paradigm of progress and profits, and to renewed confidence in the pharmaceutical industry. From where we stand, the future looks bright. 2006-12-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/482006/389274/TN_thumbnail.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/482006/389274null XML http://www.pharmexec.com/pharmexec/R%26D/PHARM-EXEC-PODCAST-Drug-Repositioning-at-Roche-A-N/ArticleStandard/Article/detail/380375?contextCategoryId=39724&ref=25 An executive interview with Lee Babiss PhD, VP, Preclinical R & D of Hoffmann-La Roche, Inc, conducted by Patrick Clinton, Editor in Chief of Pharmaceutical Executive. Tune in and hear a real-world perspective on drug repositioning as a new way of filling late-stage pipelines. 2006-10-18T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/422006/380375null REMOTE http://www.pharmexec.com/pharmexec/Thought+Leader/Smaller-is-Better/ArticleStandard/Article/detail/378065?contextCategoryId=39724&ref=25 New partnerships with nanobiotech firms are helping pharma companies overcome solubility problems and extend profitable product lifecycles. 2006-10-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/412006/378065null XML http://www.pharmexec.com/pharmexec/Articles/Learn-amp-Confirm/ArticleStandard/Article/detail/378070?contextCategoryId=39724&ref=25 In revamping its R&D department, Wyeth "really looked for people who were not going to give us the same old, 'This is how you do pharmaceutical development, dah-dah-dah,' but who could really think of different ways of doing things." 2006-10-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/412006/378070null XML http://www.pharmexec.com/pharmexec/Articles/Born-Again/ArticleStandard/Article/detail/378064?contextCategoryId=39724&ref=25 Most people have never heard of psychotic depression, but they are familiar with the case of Andrea Yates, who tragically murdered her children during an episode of the disease. 2006-10-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/412006/378064/TN_thumbnail.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/412006/378064null XML http://www.pharmexec.com/pharmexec/Global+Report/Global-Report-Please-Come-Back/ArticleStandard/Article/detail/378060?contextCategoryId=39724&ref=25 A new European collaboration of biotech, pharma, academia, and government takes up the challenge of boosting R&D. 2006-10-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/412006/378060null XML http://www.pharmexec.com/pharmexec/Articles/Benchmarking-AIDS/ArticleStandard/Article/detail/369277?contextCategoryId=39724&ref=25 Nothing reflects pharma's response to public-health crises in sharper detail than the industry's efforts to fight the AIDS epidemic. 2006-09-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/362006/369277null XML http://www.pharmexec.com/pharmexec/Washington+Report/Washington-Report-New-Partnerships-Pursue-Old-Dise/ArticleStandard/Article/detail/369268?contextCategoryId=39724&ref=25 The PPP approach asks pharma to identify promising drugs and conduct pre-clinical tests, instead of paying for costly late-stage clinical trials. 2006-09-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/362006/369268null XML http://www.pharmexec.com/pharmexec/Current+Issue/The-PharmExec-2005-Pipeline-Report/ArticleStandard/Article/detail/256552?contextCategoryId=39724&ref=25 Dry? Not quite. Instead of 1990s-style blockbusters, pharma's new molecules are niche drugs, cancer treatments and—at last—innovative mechanisms for troublesome targets. 2005-12-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/502005/256552/PE1205_TN_thumbnail.jpg XML http://www.pharmexec.com/pharmexec/From+the+Editor/From-the-Editor-Double-Standard-Drugs/ArticleStandard/Article/detail/256545?contextCategoryId=39724&ref=25 The public is focused on drug safety, but the real issue isn't approval standards. It's the way drugs expand to unapproved new indications. Are you listening, Acomplia? 2005-12-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/502005/256545/PE1205_TN_thumbnail.jpg XML http://www.pharmexec.com/pharmexec/PE+Features/The-Avian-Few-Is-it-Too-Late-for-Pharma-to-Re-ente/ArticleStandard/Article/detail/256551?contextCategoryId=39724&ref=25 Like the course of a pandemic itself, the great avian influenza scare came in waves. In 1997, the first case of the now infamous H5N1 strain of bird flu emerged in Hong Kong, infecting 18 people and killing six. In late 2003 it struck again—more than 120 people fell ill and at least 60 died over the next two years. Then this fall, David Nabarro, MD, the UN coordinator for avian and human influenza, shocked everyone when he said a bird flu pandemic could claim up to 150 million lives—a figure the World Health Organization (WHO) quickly retracted. 2005-12-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/502005/256551/PE1205_TN_thumbnail.jpg XML